InvestorsHub Logo
Post# of 252642
Next 10
Followers 38
Posts 5652
Boards Moderated 0
Alias Born 11/09/2003

Re: TheFinalCD post# 245010

Monday, 01/09/2023 8:48:46 AM

Monday, January 09, 2023 8:48:46 AM

Post# of 252642
re: APGN

Looks interesting. Up 80% inn pre-Market


EF Hutton analyst Tony Butler initiated coverage of Apexigen with a Buy rating and $8 price target. The "recently de-SPACed" biotech is developing sotigalimab as an orthogonal immunoactivating therapy in combination with immune checkpoint inhibitors and chemotherapy against a number of cancer indications, Butler tells investors.

Bladerunner
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.